Zevra Therapeutics Inc. (ZVRA)
Zevra Therapeutics Statistics
Share Statistics
Zevra Therapeutics has 54.12M shares outstanding. The number of shares has increased by 29.3% in one year.
| Shares Outstanding | 54.12M |
| Shares Change (YoY) | 29.3% |
| Shares Change (QoQ) | 1.39% |
| Owned by Institutions (%) | 70.89% |
| Shares Floating | 54.09M |
| Failed to Deliver (FTD) Shares | 4.53K |
| FTD / Avg. Volume | 0.97% |
Short Selling Information
The latest short interest is 5.91M, so 10.92% of the outstanding shares have been sold short.
| Short Interest | 5.91M |
| Short % of Shares Out | 10.92% |
| Short % of Float | 10.95% |
| Short Ratio (days to cover) | 12.86 |
Valuation Ratios
The PE ratio is -3.66 and the forward PE ratio is 11.15. Zevra Therapeutics's PEG ratio is -0.05.
| PE Ratio | -3.66 |
| Forward PE | 11.15 |
| PS Ratio | 16.34 |
| Forward PS | 1 |
| PB Ratio | 9.72 |
| P/FCF Ratio | -5.54 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zevra Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 1.52.
| Current Ratio | 2.53 |
| Quick Ratio | 2.47 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | -0.79 |
| Debt / FCF | -0.87 |
| Interest Coverage | -11.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $400.2K |
| Profits Per Employee | $-1.79M |
| Employee Count | 59 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.76 |
Taxes
| Income Tax | 15.37M |
| Effective Tax Rate | -17.05% |
Stock Price Statistics
The stock price has increased by 58.85% in the last 52 weeks. The beta is 1.94, so Zevra Therapeutics's price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | 58.85% |
| 50-Day Moving Average | 7.59 |
| 200-Day Moving Average | 7.79 |
| Relative Strength Index (RSI) | 47.71 |
| Average Volume (20 Days) | 466.56K |
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 23.61M and earned -105.51M in profits. Earnings per share was -2.28.
| Revenue | 23.61M |
| Gross Profit | 16.2M |
| Operating Income | -87M |
| Net Income | -105.51M |
| EBITDA | -76.4M |
| EBIT | -82.79M |
| Earnings Per Share (EPS) | -2.28 |
Balance Sheet
The company has 33.78M in cash and 60.3M in debt, giving a net cash position of -26.51M.
| Cash & Cash Equivalents | 33.78M |
| Total Debt | 60.3M |
| Net Cash | -26.51M |
| Retained Earnings | -505.29M |
| Total Assets | 178.13M |
| Working Capital | 51.96M |
Cash Flow
In the last 12 months, operating cash flow was -69.67M and capital expenditures 0, giving a free cash flow of -69.67M.
| Operating Cash Flow | -69.67M |
| Capital Expenditures | 0 |
| Free Cash Flow | -69.67M |
| FCF Per Share | -1.51 |
Margins
Gross margin is 68.59%, with operating and profit margins of -368.47% and -446.85%.
| Gross Margin | 68.59% |
| Operating Margin | -368.47% |
| Pretax Margin | -381.76% |
| Profit Margin | -446.85% |
| EBITDA Margin | -323.56% |
| EBIT Margin | -368.47% |
| FCF Margin | -295.04% |
Dividends & Yields
ZVRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ZVRA is $21.5, which is 199.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.5 |
| Price Target Difference | 199.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Dec 28, 2020. It was a backward split with a ratio of 1:16.
| Last Split Date | Dec 28, 2020 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | -3.36 |
| Piotroski F-Score | 3 |